Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

E 602

Next Previous
X
Search
Drug Profile

E 602

Alternative Names: Bi-Sialidase; E-602

Latest Information Update: 30 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Palleon Pharmaceuticals
  • Class Antineoplastics; Enzymes; Immunoglobulin Fc fragments; Recombinant fusion proteins
  • Mechanism of Action Neuraminidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 18 Apr 2023 Efficacy and adverse events data from a phase I trial in Solid tumours released by Palleon Pharmaceuticals
  • 18 Apr 2023 Palleon Pharmaceuticals plans a phase II trial for lung cancer and melanoma(Monotherapy) in Unknown location
  • 14 Apr 2023 Interim pharmacokinetics, pharmacodynamics, adverse events and efficacy data from a phase I/II GLIMMER-01 trial in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research(AACR-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top